UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported) March 3, 2015

 

 

Kewaunee Scientific Corporation

 

(Exact name of registrant as specified in its charter)

     
Delaware 0-5286 38-0715562
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(I.R.S. Employer
Identification No.)

 

2700 West Front Street

Statesville, North Carolina

(Address of principal executive offices)

 

 

28677

(Zip Code)

 

 

Registrant’s telephone number, including area code    704-873-7202

N/A

 

(Former name or former address, if changed since last report.)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

  

¨    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 
 

 

Item 2.02 Results of Operations and Financial Condition

 

On March 3, 2015, Kewaunee Scientific Corporation issued a press release announcing its financial results for the third quarter ended January 31, 2015. A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

 

 

Item 9.01 Financial Statements and Exhibits

 

(d) Exhibits:

  

Exhibit No.

 

99.1                    Press Release of Kewaunee Scientific Corporation dated March 3, 2015

  

In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

 

Signature

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

    (Registrant)
       Kewaunee Scientific Corporation
       
Date:  March 3, 2015      /s/ D. Michael Parker
     

D. Michael Parker

Senior Vice President, Finance

      Chief Financial Officer

 

 

 



Kewaunee Scientific Reports Results for Third Quarter

STATESVILLE, N.C., March 3, 2015 /PRNewswire/ -- Kewaunee Scientific Corporation (Nasdaq: KEQU) today reported sales and earnings for its third quarter ended January 31, 2015.

Net earnings for the quarter were $484,000, or $0.18 per diluted share, as compared to net earnings of $604,000, or $0.22 per diluted share, in the third quarter last year. Earnings for the quarter reflect lower domestic sales and an unfavorable product mix, partially offset by increased international sales.

For the nine months ended January 31, 2015, net earnings were $2,920,000, or $1.10 per diluted share, as compared to $2,916,000, or $1.11 share, in the comparable period last year.

Sales for the quarter were $27,754,000, an increase of 6.7% from sales of $26,013,000 in the third quarter last year. Domestic sales for the quarter were $20,025,000, a decline of 7.1% from sales of $21,544,000 in the third quarter last year. The domestic laboratory construction marketplace continued to be challenging during the quarter, particularly for educational laboratory construction projects, although increased bidding opportunities were experienced in certain geographic areas of the country as the overall economy continued its gradual improvement. International sales were $7,729,000, an increase of 73.0% from sales of $4,469,000 in the third quarter last year, as sales benefited from shipments of several large international orders received in earlier periods.

The order backlog was $78.0 million at January 31, 2015, down from $84.5 million at October 31, 2014, and up from $69.8 million at January 31, 2014.

Sales for the nine months ended January 31, 2015 were $88,546,000, an increase of 5.3% from sales of $84,114,000 in the comparable period last year. Domestic sales were $67,902,000, a decrease of 3.9% from sales of $70,678,000 in the comparable period last year. International sales were $20,644,000, an increase of 53.6% from sales of $13,436,000 in the comparable period last year.

Unrestricted cash on hand was $3.9 million at the end of the quarter, as compared to $6.7 million at the end of the same period last year. Short-term borrowings under the Company's bank line of credit were $798,000, as compared to $3.9 million at the end of the same period last year, and long-term debt was $4.3 million, as compared to $4.7 million. The debt-to-equity ratio was .14-to-1, as compared to .28-to-1 at the end of the same period last year. Working capital was $27.4 million, as compared to $25.5 million at the end of the same period last year.

"Historically, the third quarter is our most challenging quarter, and this was true again this year," commented David M. Rausch, Kewaunee's President and Chief Executive Officer. "However, our overall corporate performance met expectations. The continuing soft domestic educational laboratory construction market impacted sales and profit margins for the quarter. Additionally, our third quarter domestic business was impacted by both the concentration of the number of holidays and the weather conditions that affected construction project schedules. I am pleased with the sales and earnings performance of our International team, as several large international projects in our backlog shipped during the quarter. In addition, we experienced noticeable increases in orders and sales during this quarter from our expanding sales representation in Latin America.

"Looking forward, we expect sales and earnings for the fourth quarter to improve over the third quarter and be in line with results for the fourth quarter last year. Our outlook is based on scheduled ship dates for projects in our current order backlog, our recent observation that opportunities for educational laboratory construction projects have modestly improved, and our expectations that our international business will continue its progress."

About Kewaunee Scientific
Founded in 1906, Kewaunee Scientific Corporation is a recognized global leader in the design, manufacture, and installation of laboratory, healthcare, and technical furniture products. Products include steel, wood, and laminate casework, fume hoods, adaptable modular systems, moveable workstations, stand-alone benches, biological safety cabinets, and epoxy resin worksurfaces and sinks.

The Company's corporate headquarters are located in Statesville, North Carolina. Direct sales offices are located in the United States, India, Singapore, and China. Three manufacturing facilities are located in Statesville serving the domestic and international markets, and one manufacturing facility is located in Bangalore, India serving the local and Asian markets. The Company's China headquarters, sales office, and assembly operation are located in Suzhou Industrial Park, China. Kewaunee Scientific's website is located at http://www.kewaunee.com.

This press release contains statements that the Company believes to be "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact included in this press release, including statements regarding the Company's future financial condition, results of operations, business operations and business prospects, are forward-looking statements. Words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "predict," "believe" and similar words, expressions and variations of these words and expressions are intended to identify forward-looking statements. All forward-looking statements are subject to important factors, risks, uncertainties and assumptions, including industry and economic conditions that could cause actual results to differ materially from those described in the forward-looking statements. Additional information concerning these factors is contained in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this document. The Company assumes no obligation, and expressly disclaims any obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Kewaunee Scientific Corporation

Consolidated Statements of Operations (Unaudited)

(in thousands, except per share data)














Three months ended


Nine months ended




 January 31,


 January 31,




2015


2014


2015


2014

Net sales



$    27,754


$    26,013


$    88,546


$    84,114

Cost of products sold


23,298


21,302


72,120


67,934

Gross profit



4,456


4,711


16,426


16,180

Operating expenses


3,872


3,773


12,170


11,676

Operating earnings


584


938


4,256


4,504

Other income


134


95


385


265

Interest expense


(91)


(116)


(274)


(276)

Earnings before income taxes


627


917


4,367


4,493

Income tax expense


109


292


1,361


1,505

Net earnings



518


625


3,006


2,988

Less: net earnings attributable to









    the noncontrolling interest


34


21


86


72

Net earnings attributable to 









    Kewaunee Scientific Corporation


$         484


$         604


$      2,920


$      2,916











Net earnings per share attributable to









    Kewaunee Scientific Corporation stockholders







       Basic



$        0.18


$        0.23


$        1.11


$        1.12

       Diluted



$        0.18


$        0.22


$        1.10


$        1.11











Weighted average number of common









shares outstanding









       Basic



2,628


2,615


2,625


2,606

       Diluted



2,659


2,645


2,656


2,627


Kewaunee Scientific Corporation


Condensed Consolidated Balance Sheets


(in thousands)














 January 31,


April 30,






2015


2014

Assets





(Unaudited)



Cash and cash equivalents




$      3,863


$      6,248

Restricted Cash




2,524


368

Receivables, less allowances




25,062


23,473

Inventories





12,430


11,938

Prepaid expenses and other current assets




1,703


1,326

    Total Current Assets




45,582


43,353

Net property, plant and equipment




14,805


14,570

Other assets





5,063


4,794

Total Assets





$    65,450


$    62,717









Liabilities and Equity







Short-term borrowings and interest rate swap




$      1,036


$      3,150

Current portion of long-term debt




421


421

Accounts payable




12,093


8,542

Other current liabilities




4,680


4,050

    Total Current Liabilities




18,230


16,163

Other non-current liabilities




11,028


12,330

    Total Liabilities




29,258


28,493

Noncontrolling interest




306


265

Kewaunee Scientific Corporation equity




35,886


33,959

    Total Equity




36,192


34,224

Total Liabilities and Equity




$    65,450


$    62,717



Contact:

D. Michael Parker


704/871-3290





Kewaunee Scientific (NASDAQ:KEQU)
Historical Stock Chart
Von Jun 2024 bis Jul 2024 Click Here for more Kewaunee Scientific Charts.
Kewaunee Scientific (NASDAQ:KEQU)
Historical Stock Chart
Von Jul 2023 bis Jul 2024 Click Here for more Kewaunee Scientific Charts.